Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

Share Price is delayed by 15 minutes
Get Live Data
520.00    0.00 (0.00%)
Bid:
516.00
Ask:
520.00
Spread: 4.00 (0.775%)
Market Cap: £860.42m
OCI Live PriceLast checked at - London Stock Exchange

Intraday Oakley Share Chart

Share Buy-Back Programme

2 Oct 2020 07:00

RNS Number : 8803A
Oakley Capital Investments Limited
02 October 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO US PERSONS OR IN OR INTO THE UNITED STATESCANADAAUSTRALIA, THE REPUBLIC OF SOUTH AFRICAJAPAN OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

 

02 October 2020

Oakley Capital Investments Limited

 

Share Buy-Back Programme

 

Oakley Capital Investments Limited1 (the "Company") announces that the Board has authorised a buy-back programme of up to 10.0 million ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares").

 

Shareholders should be aware that a repurchase of Ordinary Shares on any trading day may represent a significant proportion of the daily trading volume in the Ordinary Shares and could exceed 25 per cent of the average daily trading volume of the preceding 20 business days.

The Company has 190,559,936 Ordinary Shares in issue and admitted to trading on the Specialist Fund Segment of the London Stock Exchange with no Ordinary Shares held in treasury. Ordinary Shares purchased by the Company will be cancelled.

- ends -

 

For further information please contact:

 

Oakley Capital Limited

+44 20 7766 6900

Steven Tredget, Investor Relations

 

Greenbrook Communications Limited

+44 20 7952 2000

Alex Jones / Gina Bell / James Williams

 

Liberum Capital Limited (Financial Adviser & Broker)

+44 20 3100 2000

Gillian Martin / Owen Matthews

 

Notes:

This announcement contains inside information for the purposes of the Market Abuse Regulation (EU) No. 596/2014

LEI Number: 213800KW6MZUK12CQ815

About Oakley Capital Investments Limited ("OCI")

OCI is a Specialist Fund Segment ("SFS") traded investment vehicle that aims to provide shareholders with consistent long-term capital growth in excess of the FTSE All-Share Index by providing liquid access to private equity returns through investment in the Oakley Funds2.

A video introduction to OCI is available at https://oakleycapitalinvestments.com/videos/

Oakley Capital, the Investment Adviser

Founded in 2002, Oakley Capital Limited has demonstrated the repeated ability to source attractive growth assets at attractive prices. To do this it relies on its sector and regional expertise, its ability to tackle transaction complexity and its deal generating entrepreneur network.

The Oakley Funds

Oakley Capital Private Equity L.P. and its successor funds, Oakley Capital Private Equity II, Oakley Capital Private Equity III, Oakley Capital IV and Oakley Capital Origin Fund are unlisted lower-mid to mid-market private equity funds that aim to provide investors with significant long-term capital appreciation. The investment strategy of the Funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement.

Important information

Specialist Fund Segment securities are not admitted to the Official List of the Financial Conduct Authority. Therefore, the Company has not been required to satisfy the eligibility criteria for admission to listing on the Official List and is not required to comply with the Financial Conduct Authority's Listing Rules.

The Specialist Fund Segment is intended for institutional, professional, professionally advised and knowledgeable investors who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFSSEFFESSEFS
Date   Source Headline
10th Nov 20224:15 pmRNSDirector/PDMR Shareholding
26th Oct 20227:00 amRNSTrading update for the 3 months ended 30 Sep 2022
13th Oct 20227:00 amRNSOakley Capital agrees partial exit from Wishcard
10th Oct 202211:55 amEQSHardman & Co Research : Q&A on Oakley Capital Investments (OCI) | 1H'22 results once again proving NAV is real and resilient
30th Sep 20223:00 pmRNSResult of AGM
20th Sep 20224:00 pmEQSHardman & Co Research on Oakley Capital Investments Ltd (OCI): 1H’22: results prove NAV real, resilient and growing
8th Sep 20227:00 amRNSInterim results for the 6 months ended 30 June 22
6th Sep 20227:00 amRNSOakley agrees follow-on investment in Facile.it
5th Sep 202212:26 pmRNSOakley Capital invests in vLex
5th Sep 20227:05 amRNSNotice of Annual General Meeting
30th Aug 202212:00 pmRNSOakley Capital invests in Phenna Group & CTS Group
26th Aug 20227:00 amRNSNotice of Results and Investor Presentation
25th Aug 20227:00 amRNSOakley Capital invests in Affinitas Education
8th Aug 20227:00 amRNSTransaction in Own Shares
27th Jul 202210:00 amRNSOakley Capital agrees partial exit from Seedtag
27th Jul 20227:00 amRNSTrading update for the 3 months ended 30 June 2022
26th Jul 20222:00 pmRNSOakley's Grupo Primavera to merge with Cegid
29th Jun 202212:50 pmRNSDirector Dealing
29th Jun 20227:00 amRNSTransaction in Own Shares
28th Jun 20227:00 amRNSTransaction in Own Shares
23rd Jun 20227:00 amRNSOakley Capital agrees sale of Facile.it
10th Jun 202211:05 amEQSHardman & Co Research: Q&A on Oakley Capital Investments: Impressive market and peer-beating 19% NAV CAGR growth 2017-21
8th Jun 20227:00 amRNSSale of Contabo and follow-on investment
16th May 20222:15 pmEQSHardman & Co Research: Oakley Capital Investments (OCI) - Capital Markets Day 2022 – let the sun shine
10th May 20227:00 amRNSDirector Dealing
9th May 20227:00 amRNSTransaction in Own Shares
6th May 20227:00 amRNSInvestment in Vice Golf
5th May 20227:00 amRNSTransaction in Own Shares
4th May 20227:00 amRNSTransaction in Own Shares
3rd May 20227:00 amRNSTransaction in Own Shares
27th Apr 20227:00 amRNSTrading update for the 3 months ended 31 March 22
19th Apr 20225:00 pmEQSHardman & Co: Q&A on Oakley Capital Investments Ltd: Proving the pudding: a sustainable growth model'
8th Apr 20221:38 pmRNSHolding(s) in Company
28th Mar 20227:00 amRNSTransaction in Own Shares
16th Mar 20222:45 pmEQSHardman & Co Research: Oakley Capital Investments Ltd (OCI) - Proving the pudding: a sustainable growth model
14th Mar 20223:04 pmRNSDirector Dealing
11th Mar 20226:17 pmRNSDirector Dealing
11th Mar 20229:08 amRNSResults analysis from Kepler Trust Intelligence
10th Mar 20227:04 amRNSShare Buy-Back Programme
10th Mar 20227:00 amRNSFinal Results for the year ended 31 December 2021
3rd Mar 20227:00 amRNSNotice of Results and Webcast Presentation
9th Feb 20228:30 amEQSHardman & Co Research: Oakley Capital Investments (OCI) Educating on education
31st Jan 202212:52 pmRNSDirector Dealing
31st Jan 202212:51 pmRNSDirector Dealing
28th Jan 20222:05 pmRNSDirector Dealing
27th Jan 20221:40 pmRNSFlash update from Kepler Trust Intelligence
26th Jan 20227:00 amRNSTrading Update for the Year Ended 31 December 2021
21st Dec 20217:00 amRNSNew Investment Advisory Agreement
17th Dec 20213:41 pmRNSHolding(s) in Company
16th Dec 20211:05 pmEQSHardman & Co Video : Hardman Talks | Everything you wanted to know about private equity but were afraid to ask!

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.